Stone, Gregg W <br/><br/>
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.  [electronic resource] 

 -  Journal of the American College of Cardiology  Jan 2015 
 - 27-38 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-3597 
<br/><br/><label>Standard No.: </label>10.1016/j.jacc.2014.10.029  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antithrombins--adverse effects<br/>Drug Therapy, Combination<br/>Female<br/>Heparin--therapeutic use<br/>Hirudins--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--mortality<br/>Peptide Fragments--adverse effects<br/>Percutaneous Coronary Intervention<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Recombinant Proteins--adverse effects